Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
big bidder out there
Bid: 1.68 x 24800
Ask: 1.72 x 4400
PRAN had a wild day yesterday... trading on pran has changed wildly in january... it went from being a spike and sell stock to a steady climber. I suspect that some kind of staircase action has started... after january effect, pps went back to 200sma on a nice news day and rebounded. watch for retests of major moving averages on the way up... if it closes this week above the 50sma... this chart is going to attract some serious $$$
http://stockcharts.com/h-sc/ui?s=PRAN&p=D&yr=0&mn=6&dy=0&id=p51582470932
this is still a stealth play.
200sma is a reasonable target.
.073 next!
Great!
Well, the answer to your question is yes.
NEW YORK (TheStreet) -- Shares of Keryx Biopharmaceuticals(KERX_) and Aeterna Zentaris(AEZS_) soared March 5 after an article touting the prospects of the drug companies was published on the investor Web site Seeking Alpha.
But the credibility of the author, Jeremy Richards, and the veracity of claims and statements made by him, couldn't be verified by anyone at his purported investment firm, the drug companies and Seeking Alpha.
Richards is the writer of 14 Seeking Alpha articles over two years promoting Keryx, Aeterna and the experimental cancer drug perifosine that both companies are jointly developing. Richards' latest article on the two stocks was published March 2. Richards called perifosine's Food and Drug Administration approval "practically a done deal" and predicts positive results from an ongoing colon cancer clinical trial.
Keryx, based in New York, is expected to announce top-line results next month from a phase III study of perifosine in advanced colon cancer. The trial is likely to fail based on poor phase II data as well as a proprietary analysis correlating the low market values of cancer drug developers with high failure rates for phase III cancer drug trials.
In response to Richards' article, Keryx shares jumped $1.24, or 33%, to $4.94 in Nasdaq trading March 5, adding $100 million to the micro-cap company's market value. Shares of Quebec-based Aeterna rose 40 cents, or 23%, to $2.15, adding $33 million in market value.
Neither company released news that would have propelled the shares. Keryx last released a media statement Feb. 29, when it said its 2011 loss widened while its cash holdings increased. Aeterna last published a release Feb. 3, an update on a phase I prostate cancer treatment.
Investors in little-known biotechnology stocks follow professionals for insights on what's often complex scientific information. Keryx and Aeterna aren't followed closely by Wall Street analysts, and most mutual fund managers don't hold stocks that cost less than $5, as the two drug companies do.
Richards describes himself as the manager and director of Private Wealth Fund with "twenty years investment experience," according to his Seeking Alpha profile. That helps explain why his Keryx and Aeterna analyses seem so well-received.
But Richards may not be the investment pro he claims to be. Reached March 2 by phone, Peggy Gan, CEO of Private Wealth Fund, a California-registered limited liability corporation, says she has never heard of Richards.
"I don't want to cast aspersions on the guy but no one named Jeremy Richards works for Private Wealth Fund," Gan said. She also said she had no knowledge of any articles published on Seeking Alpha.
Richards didn't respond to a message sent through his Seeking Alpha account. No other information about his whereabouts or investor credentials could be found.
Seeking Alpha has started a "dispute process" with Richards. He's being asked to provide documentation to confirm the veracity of his Keryx and Aeterna articles, according to George Moriarty, managing editor of Seeking Alpha.
"The process is ongoing," Moriarty said. "We will investigate any and all disputes registered against articles published on Seeking Alpha."
Add Comment
inShare
1
1 2 3 Last »Next ›
More from TheStreet
5 Stocks Under $5 Making Big Moves
'Mad Money' Recap: Next Week's Game Plan (Final)
10 Stocks Owned by the Best Fund Managers (Update2)
Market Preview: Apple Takes a Breather
'Mad Money Lightning Round': Go for Philip Morris International
From Around the Web
Yahoo Stabs Facebook In The Back, Says Pay For Its Patents Or Get Sued (TechCrunch)
Letter to the Editor: My Take on the Renewable Energy Certificates (Patch - Reading, MA)
[?]
Kerx has been in a downward spiral since their last pipe. Aezs has chosen ATM financing and has gone up, mostly, since announcing it. Interesting arbitrage.
I am watching AEZS/KERX going nuts right now... someone has to be wrong.
wow... nothing better than nice tan dark skin contrasted with white.
even though europe has it's ltro2 or whatever it's called, bernanke said qe3 is off. so the updraft we've seen in all stocks is all due to earnings, worldwide money printing, or "operation twist" backdraft.
nasdaq has three gaps to close beneath.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67242441&txt2find=qe
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70814950&txt2find=gap
tight tangle of moving averages can happen with tight sideways action, but low float, you get explosive volatility as well.
JBII has tweaked their old processor and processor #2 is operational.
processor #1 was moved to fit #2 and they have built a "fabrication building" to build processors because you can't weld while making fuels.
Plastic is premelted now and can run with a continuous flow.
Different fuels are distilled at different towers.
http://plastic2oil.com/site/evolution
still no cost feedstock
"back out the metal"
after a bump off of cloud support! (june 2011)
13/20/50 booshacological
17,600 @ $1.45... Good luck!
Gap pretty much closed... Bought 782 shares
nice reversal and nice close but volume was weak.
Awe, come on, close that gap!
Not at all.
Good for them.
I am going to buy the gap closure.
AFFY... anyone see the 700 shares at $4.35 go through this morning?
I tried to get some at $4.50
CRIS /HSP90
thanks, after I posted my hunch I looked it up more and thought about it... cancer cells are like ferraris, or crack addicts, or small cap biotechs.... they burn through resources.
[OT] funny thing about that link, when I posted it this morning it was listed as land, the house on the property was "in the fine print".
now, I click it and it gives the house data.
Is the MOA is something along the lines of: if hsp90 allows genotypic variation in a protein to exist, it could mask oncogenic mutations from immune survelance.
Inhibit HSP90 and the protein resulting from an oncogenic mutation is either exposed to immune survelance, or may become nonfunctional due to misfolding?
[OT] 1.39 acres, advertised as land only, even though there is a small old house on the lot... $875,000
http://www.trulia.com/property/3049045024-29-Myles-Standish-Rd-Weston-MA-02493
BLRX...Despite the low price for the shares, seems to be trading quite strongly, and, it has closed the gap.
maybe it is the healthy price on the warremts. I am paying attention to the price of the gap up as well as the price of the first day on the naz and also to the price of the warrants, going forward.
I sold about 25% at $5.88
good for you! I made bucks on the suprise run 4 years ago and was back in and out to preserve the gain.
But ARIA almost always sells off on earnings day so I think it more likely that it taps a new high someday before the date.
CORT... jq1234 and pcrutch... stock is trading very bearishly going into feb 17. A lot of people think FDA is going to ask for another trial. I am out of it. Any thoughts? Very little info on Ihub... a good amount of thought on Yahoo though...and Adam F..
http://www.thestreet.com/story/11410625/1/biotech-stock-mailbag-corcept-therapeutics-reader-retorts.html
looking back at old charts and patterns (see previous post in this thread for reference)
my gut has been bearish for a while... the two gaps on the naz near the 200sma have been bugging me for a long time... and there's that other one right there... could there be anything fundamental that will cause naz to NOT close the gaps? like the absence of prop trading or something? what... the computers aren't going to try to close those gaps because they've all been turned off?